Pasar al contenido principal

INMUNOINTERACTOMA DE RECEPTORES LINFOCITICOS Y PEQUEÑOS PEPTIDOS DERIVADOS DE LNCRNAS ESPECIFICOS DE CANCER DE OVARIO

PID2021-124564OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DA CORUÑA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Thanksgiving to Yeast, the HMGB Proteins History from Yeast to Cancer [Review]

  • Lamas, Mónica
  • Vizoso-Vázquez, Ángel
  • Barreiro-Alonso, Aida
  • Cámara-Quílez, M.
  • Cerdán, María Esperanza
This article belongs to the Special Issue Yeasts Biochemistry and Biotechnology, [Abstract] Yeasts have been a part of human life since ancient times in the fermentation of many natural products used for food. In addition, in the 20th century, they became powerful tools to elucidate the functions of eukaryotic cells as soon as the techniques of molecular biology developed. Our molecular understandings of metabolism, cellular transport, DNA repair, gene expression and regulation, and the cell division cycle have all been obtained through biochemistry and genetic analysis using different yeasts. In this review, we summarize the role that yeasts have had in biological discoveries, the use of yeasts as biological tools, as well as past and on-going research projects on HMGB proteins along the way from yeast to cancer., This research was funded by Plan Estatal I+D+i, Instituto de Salud Carlos III (ISCIII, Spain) (grant nos. PI14/01031 and PI18/01417) and Ministerio de Ciencia e Innovación (grant no. PID2021-124564OB-I00), and cofunded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe” and by Xunta de Galicia (Consolidación Grupos Referencia Competitiva grant no. ED431C 2020-08), Xunta de Galicia; ED431C 2020-08
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Long Non-Coding RNA–Derived Peptides as a Novel Source of Tumor Neoantigens: Expanding the Immunopeptidome Beyond Canonical Coding Regions

  • López-Calvo, I.
  • Bao-Camacho, I.
  • Martín-Revuelta, Samuel
  • Rey Souto, Cora
  • Franco-Gacio, Anahir
  • Pérez-Martínez, José Manuel
  • Sandino Somoza, Iván
  • Mourenza Flórez, Álvaro
  • Rodríguez-Belmonte, Esther
  • Lamas, Mónica
  • Cerdán, María Esperanza
  • Barreiro-Alonso, Aida
  • Vizoso-Vázquez, Ángel
[Abstract] Cancer immunotherapy has transformed the clinical management of several malignancies; however, its efficacy remains limited in tumors with low mutational burden and restricted availability of classical mutation-derived neoantigens. In this context, increasing evidence indicates that the tumor immunopeptidome extends far beyond canonical protein-coding regions, incorporating peptides derived from non-coding transcripts through non-canonical translation mechanisms. Long non-coding RNAs (lncRNAs), traditionally regarded as transcriptional or post-transcriptional regulators, have recently emerged as an unexpected source of small open reading frame-encoded peptides (lncPEPs). A subset of these peptides is processed and presented by major histocompatibility complex class I molecules, generating tumor-specific neoantigens capable of eliciting CD8+ T cell responses. Owing to the high tissue and context specificity of lncRNA expression, lncRNA-derived neoantigens offer unique advantages over mutation-based targets, including increased tumor selectivity and potential recurrence across patient subsets. In this review, we synthesize current knowledge on the biogenesis, detection, and immunogenic potential of lncRNA-derived peptides, highlighting experimental and computational strategies for their identification within the cancer immunopeptidome. We discuss the challenges associated with their validation and clinical translation, as well as their relevance for the development of vaccines and adoptive T cell–based therapies. Finally, we illustrate these concepts using epithelial ovarian cancer as a representative model of low-mutational-burden tumors, where lncRNA-derived neoantigens may help overcome current limitations of immunotherapy and enable patient stratification for personalized treatment approaches., This research was funded by Instituto de Salud Carlos III, Spain, (grant no. FORT23/00010) and the Ministerio de Ciencia e Innovación (grant no. PID2021-124564OB-I00) and by the Xunta de Galicia, Spain (Consolidación Grupos Referencia Competitiva, grant no. ED431C 2024-01); and co-funded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe. C.R.-S. was funded by a predoctoral fellowship from FPU-2021 (Spain). A.F.-G. was funded by a predoctoral fellowship from FPU-2022 (Spain). J.M.P.-M. was funded by a predoctoral fellowship from FPU-2022 (Spain). I.L.-C. was funded by a predoctoral fellowship from Xunta de Galicia-2025 (Spain). I.B.-C. was funded by a predoctoral fellowship from Xunta de Galicia-2025 (Spain), Xunta de Galicia; ED431C 2024-01
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

  • Salamini-Montemurri, Martín
  • Lamas, Mónica
  • Lorenzo-Catoira, Lidia
  • Vizoso-Vázquez, Ángel
  • Barreiro-Alonso, Aida
  • Rodríguez-Belmonte, Esther
  • Quindós-Varela, María
  • Cerdán, María Esperanza
This article belongs to the Special Issue Non-coding RNAs' Functionality-Diagnosis and Therapy in Cancer and Other Indications, [Abstract] Epithelial ovarian cancer (EOC) is one of the deadliest gynecological cancers worldwide, mainly because of its initially asymptomatic nature and consequently late diagnosis. Long non-coding RNAs (lncRNA) are non-coding transcripts of more than 200 nucleotides, whose deregulation is involved in pathologies such as EOC, and are therefore envisaged as future biomarkers. We present a meta-analysis of available gene expression profiling (microarray and RNA sequencing) studies from EOC patients to identify lncRNA genes with diagnostic and prognostic value. In this meta-analysis, we include 46 independent cohorts, along with available expression profiling data from EOC cell lines. Differential expression analyses were conducted to identify those lncRNAs that are deregulated in (i) EOC versus healthy ovary tissue, (ii) unfavorable versus more favorable prognosis, (iii) metastatic versus primary tumors, (iv) chemoresistant versus chemosensitive EOC, and (v) correlation to specific histological subtypes of EOC. From the results of this meta-analysis, we established a panel of lncRNAs that are highly correlated with EOC. The panel includes several lncRNAs that are already known and even functionally characterized in EOC, but also lncRNAs that have not been previously correlated with this cancer, and which are discussed in relation to their putative role in EOC and their potential use as clinically relevant tools., This research was funded by the Plan Estatal I + D + i, Instituto de Salud Carlos III (ISCIII, Spain grant no. PI18/01417) and the Ministerio de Ciencia e Innovación (grant no. PID2021-124564OB-I00), and co-funded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe” and by the Xunta de Galicia (Consolidación Grupos Referencia Competitiva grant no. ED431C 2020-08). M.S.-M. acknowledges the Ministry of Science, Innovation, and Universities of Spain for funding through an FPU fellowship, Xunta de Galicia; ED431C 2020-08
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

The Effect of HMGB1 and HMGB2 on Transcriptional Regulation Differs in Neuroendocrine and Adenocarcinoma Models of Prostate Cancer

  • Salamini-Montemurri, Martín
  • Vizoso-Vázquez, Ángel
  • Barreiro-Alonso, Aida
  • Lorenzo-Catoira, Lidia
  • Rodríguez-Belmonte, Esther
  • Cerdán, María Esperanza
  • Lamas, Mónica
This article belongs to the Special Issue Recent Molecular Biology on Ovarian Cancer and Prostate Cancer, [Abstract] Human high-mobility group-B (HMGB) proteins regulate gene expression in prostate cancer (PCa), a leading cause of oncological death in men. Their role in aggressive PCa cancers, which do not respond to hormonal treatment, was analyzed. The effects of HMGB1 and HMGB2 silencing upon the expression of genes previously related to PCa were studied in the PCa cell line PC-3 (selected as a small cell neuroendocrine carcinoma, SCNC, PCa model not responding to hormonal treatment). A total of 72% of genes analyzed, using pre-designed primer panels, were affected. HMGB1 behaved mostly as a repressor, but HMGB2 as an activator. Changes in SERPINE1, CDK1, ZWINT, and FN1 expression were validated using qRT-PCR after HMGB1 silencing or overexpression in PC-3 and LNCaP (selected as an adenocarcinoma model of PCa responding to hormonal treatment) cell lines. Similarly, the regulatory role of HMGB2 upon SERPINE1, ZWINT, FN1, IGFPB3, and TYMS expression was validated, finding differences between cell lines. The correlation between the expression of HMGB1, HMGB2, and their targets was analyzed in PCa patient samples and also in PCa subgroups, classified as neuroendocrine positive or negative, in public databases. These results allow a better understanding of the role of HMGB proteins in PCa and contribute to find specific biomarkers for aggressive PCa., This research was funded by the Plan Estatal I + D + i, Instituto de Salud Carlos III (ISCIII, Spain, grant no. PI18/01417 and Fortalece FORT23/00010) and the Ministerio de Ciencia e Innovación (grant no. PID2021-124564OB-I00), and co-funded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe” and by the Xunta de Galicia (Consolidación Grupos Referencia Competitiva, grant no. ED431C 2020-08). M.S.-M. acknowledges the Ministry of Science, Innovation, and Universities of Spain for funding through an FPU fellowship, Xunta de Galicia; ED431C 2020-08
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Circulating lncRNA Landscapes: Redefining Biomarker Discovery in Ovarian Cancer

  • Lorenzo-Catoira, Lidia
  • Vizoso-Vázquez, Ángel
  • Barreiro-Alonso, Aida
  • Cerdán, María Esperanza
  • Rodríguez-Belmonte, Esther
  • Lamas, Mónica
This is the ACCEPTED VERSION of the peer-reviewed article. The published manuscript is available at EurekaSelect via https://www.eurekaselect.com/openurl/content.php?genre=article&doi=10.2174/0109298673492387260806065240, [Abstract] Ovarian cancer (OC) is an aggressive disease with nonspecific clinical manifestations that is frequently diagnosed at advanced stages, drastically reducing the 5- year survival rate, due in part to the absence of specific biomarkers. Owing to its high sensitivity and reproducibility, low cost, and minimal invasiveness, liquid biopsy is a promising technique for OC. Although proteins, ctDNA, and miRNAs have been widely studied as biomarkers, lncRNAs are more advantageous due to their cell- and tissue-specific expression and high stability. Several lncRNAs with potential as liquid biomarkers in OC have been characterized, but none are currently used clinically. The study has analysed 662 lncRNAs deregulated in OC to determine their ability to be detected in biofluids. Twenty-three have been identified in blood samples, four in ascites, and twenty- seven in extracellular vesicles isolated from biofluids. Most of these lncRNAs have an oncogenic role and have been associated with poor prognosis, primarily overall survival. Regarding their diagnostic value, some have even been positively associated with FIGO stages, but only one, included in the panel RP5-837J1.2/miR-361-3p/PELI3, allows differentiation between patients in early stages and healthy women. Information on lncRNAs detected in biofluids related to cancer hallmarks has also been included to identify gaps in the field and to serve as a guide for future research., This article was funded by Ministerio de Ciencia e Innovación PID2021- 124564OB-I00 AEI/10.13039/501100011033/ FEDER, UE, and cofunded by Xunta de Galicia (Consolidación Grupos Referencia Competitiva GRC grant no. ED431C 2024/01)., Xunta de Galicia; ED431C 2024/01